Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.
RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Nature. 2024 Sep;633(8031):878-886. doi: 10.1038/s41586-024-07960-6. Epub 2024 Sep 18.
Persistent colonization and outgrowth of potentially pathogenic organisms in the intestine can result from long-term antibiotic use or inflammatory conditions, and may perpetuate dysregulated immunity and tissue damage. Gram-negative Enterobacteriaceae gut pathobionts are particularly recalcitrant to conventional antibiotic treatment, although an emerging body of evidence suggests that manipulation of the commensal microbiota may be a practical alternative therapeutic strategy. Here we isolated and down-selected commensal bacterial consortia from stool samples from healthy humans that could strongly and specifically suppress intestinal Enterobacteriaceae. One of the elaborated consortia, comprising 18 commensal strains, effectively controlled ecological niches by regulating gluconate availability, thereby re-establishing colonization resistance and alleviating Klebsiella- and Escherichia-driven intestinal inflammation in mice. Harnessing these activities in the form of live bacterial therapies may represent a promising solution to combat the growing threat of proinflammatory, antimicrobial-resistant Enterobacteriaceae infection.
肠道中潜在致病性生物体的持续定植和生长可能是由于长期使用抗生素或炎症引起的,并且可能会使免疫失调和组织损伤持续存在。革兰氏阴性肠杆菌科肠道共生菌对常规抗生素治疗特别具有抵抗力,尽管越来越多的证据表明,操纵共生菌群可能是一种实用的替代治疗策略。在这里,我们从健康人的粪便样本中分离并筛选出能够强烈且特异性抑制肠道肠杆菌科的共生细菌联合体。其中一个精心设计的联合体由 18 种共生菌株组成,通过调节葡萄糖酸盐的可用性有效地控制生态位,从而重新建立定植抗性并缓解小鼠的克雷伯菌和大肠杆菌驱动的肠道炎症。以活菌治疗的形式利用这些活性可能是应对日益严重的促炎、抗微生物耐药性肠杆菌科感染威胁的有希望的解决方案。